Scout Investments, Inc, an affiliate of Carillon Tower Advisers, released the “Carillon Scout Small Cap Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. In the second quarter, the small-cap growth market was down. Higher quality, earners, and larger small caps were among the traits of many of the stocks that outperformed higher-priced securities. Consumer staples and communication services were among the Russell 2000® Growth Index’s top-performing sectors; real estate and consumer discretionary were among the worst-performing. During the second quarter, the S&P 500 Index beat the Russell 2000® Index by almost 7.6%. In comparison to their large-cap counterparts, small-cap valuations remain attractive, and they are cheaper when compared to historical ratios. In addition, please check the fund’s top five holdings to know its best picks in 2024.
Carillon Scout Small Cap Fund highlighted stocks like Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), in the second quarter 2024 investor letter. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a biopharmaceutical company. The one-month return of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was -8.18%, and its shares gained 10.95% of their value over the last 52 weeks. On September 13, 2024, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stock closed at $31.11 per share with a market capitalization of $1.728 billion.
Carillon Scout Small Cap Fund stated the following regarding Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in its Q2 2024 investor letter:
“Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a biopharmaceutical company focused on developing and commercializing products to treat central nervous system diseases. Management reiterated uninspiring revenue guidance after the U.S. Food and Drug Administration issued a disappointing progress report regarding a key drug.”
A lab technician analyzing a sample in a laboratory, showing the rigorous research conducted by the biopharmaceutical company.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 16 hedge fund portfolios held Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) at the end of the second quarter which was 18 in the previous quarter. In the second quarter of 2024 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reported $168.3 million in net revenues compared to $135.5 million in Q2 2023. While we acknowledge the potential of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In addition, please check out our hedge fund investor letters Q2 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.
